Clinical trials: Single Dose
Hepatic Fibrosis
QTc Assessment in a Single-Dose Study of Hydronidone Capsules
This study was designed with three dose cohorts (A1-A3): a 90 mg cohort, a 270 mg cohort, and a 540 mg cohort. Each cohort enrolled 16 healthy Chinese participants, with 12 receiving the investigational product Hydronidone…
- Trial name
- NCT07263152
- Testing
- Hydronidone
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Hypertension
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Amlodipine in Healthy Male Subjects
The purpose of this study is to evaluate the pharmacokinetics and safety when administrated Fimasartan/Amlodipine and when co-administrated Fimasartan and Amlodipine.
- Trial name
- NCT02920047
- Testing
- Fimasartan/Amlodipine, Fimasartan + Amlodipine
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Human Immunodeficiency Virus
Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers
The study is a Phase 1, randomized, double-blinded, placebo-controlled, sequential single dose escalation safety, tolerability and pharmacokinetic study of subcutaneous and intramuscular TMB-607 administered to HIV-negative…
- Trial name
- NCT03110549
- Testing
- TMB-607
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- TaiMed Biologics Inc.
Healthy
A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants
The purpose of this study is to assess the safety and tolerability of ibrutinib, to compare the pharmacokinetics of ibrutinib after single oral administration of 840 mg and 1680 mg and to assess the effects of a single dose of…
- Trial name
- NCT02271438
- Testing
- Ibrutinib, Moxifloxacin
- Where
- Belgium
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes Mellitus
A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-8521. Part 1 primary hypothesis: Administration of single subcutaneous (SC) doses of MK-8521 is sufficiently safe and well- tolerated…
- Trial name
- NCT02055547
- Testing
- MK-8521 35μg, MK-8521 100μg, MK-8521 125μg
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Peripheral Arterial Diseases
PK Study to Evaluate the Effect of PLC on Healthy Chinese Subjects by Multiple-doses
The main objective is to evaluate the effect of Propionyl-L-Carnitine Hydrochloride on clinical pharmacokinetic characteristics and its effect of clinical pharmacokinetic characteristics and safety on healthy Chinese subjects to…
- Trial name
- NCT02786043
- Testing
- Propionyl-L-Carnitine Hydrochloride
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Lee's Pharmaceutical Limited
Mesothelioma, Pancreatic Cancer
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
This research is being conducted to determine the biodistribution of radiolabeled amatuximab in tumor and non-tumor tissues in subjects with mesothelin over expressing cancer including mesothelioma, pancreatic, ovarian or non…
- Conditions
- Mesothelioma, Pancreatic Cancer, Ovarian Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT01521325
- Testing
- Amatuximab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Morphotek
Celiac Disease
Study of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal
ALV003-0812 is a study of the safety and tolerability of a study drug (ALV003) in healthy adult volunteers and in patients with well-controlled celiac disease, following a meal that contains gluten.
- Trial name
- FED (NCT00669825)
- Testing
- ALV003
- Where
- 2 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Alvine Pharmaceuticals Inc.
Stroke, Stroke, Acute
Phase 1 Study to Assess AER-271
The objective of this Phase 1 trial is to assess the safety, tolerability and pharmacokinetics of AER-271 in health subjects.
- Conditions
- Stroke, Stroke, Acute, Stroke, Ischemic
- Trial name
- NCT03804476
- Testing
- AER-271
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Aeromics, Inc.
Ovarian Cancer, Breast Cancer
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid…
- Conditions
- Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- PETRA (NCT04644068)
- Testing
- AZD5305, Paclitaxel, Carboplatin
- Where
- 68 sites in United States, Australia and 12 more
- Volunteers
- 702 people
- Sponsor
- AstraZeneca
Healthy Subjects
Single Dose Study To Study The Absorption, Metabolism And Excretion Of Famitinib
The purpose of this study is to evaluate the excretion balance, metabolic profile and the routes of excretion of famitinib in healthy adult male subjects.
- Trial name
- NCT05473468
- Testing
- Famitinib
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Parkinson's Disease
Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women
The purpose of this study is to fulfil regulatory requirements for registration of a new chemical entity in China. Rasagiline is approved for the treatment of Parkinson's Disease (PD) in Europe and the US.
- Trial name
- NCT01652313
- Testing
- Rasagiline
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Recurrent Glioblastoma Multiforme
Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)
The purpose of this study is to evaluate the anti-tumor activity and safety of Panzem NCD given in combination with daily oral fixed-dose temozolomide in patients with recurrent glioblastoma multiforme.
- Trial name
- NCT00481455
- Testing
- Panzem NCD, Temozolomide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- CASI pharmaceuticals, Inc.
Healthy Volunteer
Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Participants
The primary objective of the study is to evaluate the safety and tolerability of single- and multiple-ascending oral doses of BIIB095 in healthy participants.
- Trial name
- NCT03454126
- Testing
- BIIB095
- Where
- 2 sites in United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Biogen
Healthy Subjects
Effect of Rifampicin on the Pharmacokinetics of SHR6390 in Healthy Subjects
The primary objective of the study is to evaluate the effect of rifampicin on pharmacokinetics of healthy Chinese adult subjects after oral administration of SHR6390 tablets.
- Trial name
- NCT04439578
- Testing
- SHR6390 tablet single oral dose of SHR6390 or co-administered with rifampicin
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy
A Study in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1291583 in healthy male and female subjects following oral administration of multiple rising doses over 4 weeks.
- Trial name
- NCT03868540
- Testing
- BI 1291583
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteer
A Study of Administration of RoActemra/Actemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers
This open-label, multi-center study will compare the bioavailability of RoActemra/Actemra (tocilizumab) administration by auto-injector versus pre-filled syringe in healthy volunteers.
- Trial name
- NCT01418989
- Testing
- tocilizumab [RoActemra/Actemra] Syringe, tocilizumab [RoActemra/Actemra] auto-injector
- Where
- 2 sites in France
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Hepatic Impairment
Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK
This study was to investigate the pharmacokinetic (PK) and safety of M2951 (Bruton's tyrosine kinase [BTK] inhibitor) in participants with different degrees of hepatic impairment compared to participants with normal hepatic…
- Trial name
- NCT04546789
- Testing
- M2951 (BTK inhibitor)
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Healthy Subjects
Comparison of Pharmacokinetics of Infacort® Versus Immediate-release Hydrocortisone
This was a single centre, open-label, randomised, 5-way crossover study.
- Trial name
- NCT02777268
- Testing
- Infacort, Hydrocortisone
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Neurocrine UK Limited
Non-Small Cell Lung Cancer
Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®
To determine the optimal dose and schedule of Fusilev to prevent or reduce Folotyn-related Grade 3 or higher oral mucositis in patients with Non-Small Cell Lung Cancer.
- Trial name
- NCT01820091
- Testing
- Folotyn, Fusilev
- Sponsor
- Acrotech Biopharma Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.